Rubicon Research IPO GMP & Review: Should You Apply or Avoid?

Check Expert’s Verdicts on Rubicon Research IPO

Rubicon Research’s IPO is open for bidding from 9th October 2025 to 13th October 2025. It is a book-building IPO of ₹1,377.50 crores, comprising an entirely fresh issue of ₹1.03 crores.  The problem will be listed on BSE and NSE on its tentative listing date, 16th October 2025. 

Rubicon Research IPO Details 

The Rubicon Research IPO date is fixed between 9th October 2025 and 13th October 2025. The face value of Rubicon Research’s IPO shares is ₹1 per share, and the IPO price is set between ₹461 and ₹485 per share.

MUFG Intime India Private Limited is the registrar of the Rubicon Research IPO and is responsible for managing the allotment process and initiating refunds. Check out the latest IPO details in the table below. 

Rubicon Research IPO Share Reservation

Rubicon Research’s IPO is a book-building issue of ₹1,377.50 crores, comprising a new issue that will be listed on the BSE and NSE Exchanges. Furthermore, SEBI has specified the share reservation criteria for different investor categories. 

Rubicon Research IPO GMP Grey Market Premium

GMP is the gap between the price band of the issue and the price at which company shares are currently trading in the grey market. Would you like to receive live updates on the Rubicon Research IPO? If yes, then you’ve reached the right spot. Check the table below to learn about the GMP trends.

As of October 03, 2025, Rubicon Research’s IPO GMP stands at ₹0 per share, indicating that the share is likely to list at ₹485 on its tentative listing date, October 16, 2025.

GMP data is subject to change based on market trends and sentiments. Please verify the live GMP status before applying for the Rubicon Research GMP. Stay informed with Univest to know about real-time insights on IPOs and their GMP trends. 

Rubicon Research IPO GMP Review

Check out the detailed Rubicon Research GMP IPO review for a thorough understanding of its potential and the listing gains expected on 16th October 2025. The Rubicon Research IPO review below will help you invest effectively to avoid significant losses. Explore more to make informed investment decisions on this IPO. 

Financial Health

Assess a company’s financial performance to know about its ability to sustain a competitive edge. Therefore, it is crucial to understand the business’s financial growth margins and declines before applying for the Rubicon Research IPO.

Rubicon Research Limited’s revenue increased by 49% from ₹872.39 crore in March 2024 to ₹1,296.22 crore in March 2025. Moreover, the company’s PAT rose by 48% from ₹91.01 crores to ₹134.36 crores.

Rubicon Research Limited’s IPO has demonstrated consistent revenue growth, indicating that the company is financially stable. Moreover, brokers, investors, and RAs have a positive outlook for the Rubicon Research IPO on its tentative listing date,16th October 2025.  

Technical Analysis

Several technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technical aspects of the Rubicon Research IPO.

The P/E ratio of Rubicon Research Limited’s share is [.], and its Earnings Per Share (EPS) stands at 8.70. Thus, the Rubicon Research Limited IPO can deliver gains on its tentative listing date, 14th October  2025. 

Note: The data, as mentioned above, is taken from authentic sources and highlights pre-issue information. The PE ratio and EPS of Rubicon Research Limited are subject to change following the IPO. Refer to the table below for post-issue updates on these two metrics. 

Rubicon Research IPO Subscription Status

The Rubicon Research IPO is scheduled to open for bidding on October 7, 2025. The subscription status for this IPO is yet to be announced. Stay informed on this passage to check the live Rubicon Research IPO subscription status. 

About Rubicon Research Limited

Rubicon Research Limited, established in 1999, is a pharmaceutical company engaged in the development, manufacturing, and commercialisation of differentiated formulations. As of June 30, 2025, Rubicon Research had a portfolio of 72 active Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) products approved by the US FDA. The company’s portfolio includes 66 commercialised products, with a US generic pharmaceutical market size of USD 2,455.7 million, of which Rubicon Research Limited contributed USD 195 million in Fiscal 2024. As of June 30, 2025, the company has 17 new products awaiting US FDA ANDA approval and 63 products at various stages of development. As of June 30, 2025, the company marketed over 350 SKUs to 96 customers, including three major wholesalers who account for more than 90% of wholesale drug distribution in the US. The company also supplies group purchasing organisations (GPOs), national pharmacy chains, regional pharmacy chains, and managed care organisations.     

Rubicon Research Limited Financials

The company’s financial analysis is essential before applying for the Rubicon Research  IPO. Refer to the table to learn about Rubicon Research Limited’s financial information. 

Explanation

Rubicon Research Limited’s revenue increased by 49% from ₹872.39 crore in March 2024 to ₹1,296.22 crore in March 2025. Moreover, the company’s PAT rose by 48% from ₹91.01 crores to ₹134.36 crores.

Rubicon Research IPO Bidding Requirements

Investors can bid for a minimum of 46 shares and in multiples thereof. The following table represents the minimum and maximum investments by individual investors (retail) and HNI in terms of shares and amount.

Rubicon Research’s IPO has reserved lot sizes for different investor categories. Refer to the table below to view the requirements for applying to this IPO.

Use the lot size calculator to find how many shares you should apply for!

Rubicon Research IPO Promoter Holding

Refer to the table below to review the holdings of Rubicon Research Limited’s promoters: Sanjay Singhania, Ajay DD Singhania, Bajrang Bothra, Laxmi Pat Bothra and Nikhil Bothra.

Note: The value will be calculated using Equity Dilution = Share Holding Pre-Issue –  Share Holding Post-Issue.

Aim of the Rubicon Research IPO

The primary aim of the Rubicon Research IPO is to raise ₹52.91 crore. On the other hand, Rubicon Research has decided to utilise these funds in different ways.

1. To Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by the Company
2. To fund inorganic growth through unidentified acquisitions and other strategic initiatives, and General corporate purposes

Should I Invest in the Rubicon Research IPO?

Explore the pros and cons of Rubicon Research to know whether you should apply or avoid the issue. These pros and cons may help you understand the IPO’s efficiency in generating profits in the coming decades. 

Pros of Rubicon Research IPO

• The company is the fastest-growing Indian pharmaceutical company among its peers.
• The company has strong R&D capabilities
• The company has a data-driven product selection framework

Cons of Rubicon Research IPO

• The company has a high revenue concentration in the US market
• The company has R&D uncertainty
• The company has a dependence on the manufacturing from third parties

How to Apply for the Rubicon Research IPO?

Please follow the steps outlined below to apply for a position at Rubicon Research Limited.

• Step 1: Conduct thorough research on the Rubicon Research IPO, including GMP, subscription status, issue size, lot size, and other relevant details. 
• Step 2: Open a demat account with Univest to gain real-time insights into GMP and subscription status. You can also use your previous demat account by navigating to the IPO section. 
• Step 3: Place a bid for one lot of 30 shares, valued at ₹ 14,550.
• Step 4: You will receive a mandate request after making a bid. Approve the request to proceed further.    

Note: You can apply for the Rubicon Research IPO from more than one demat account to increase your chances of allotment. 

How to Check Rubicon Research IPO Allotment Status?

You can check whether the Rubicon Research IPO allotment has been completed in various ways. These include NSE and the registrar portal. Refer to the steps below to check your allotment status online.

Check On BSE

• Visit the BSE Official Website.
• Navigate to the IPO Allotment Section. 
• Select Equity as the issue type. 
• Choose the Rubicon Research IPO.  
• Choose whether to proceed with the PAN number or the application number. 
• Submit your details to get the allotment status online. 

Check On the Registrar Portal

• Visit the registrar portal.
• Click on the allotment option.
• Fill in the required details.
• Click on the submit button to know your Rubicon Research IPO allotment status.

Let’s Wrap

Rubicon Research’s IPO is a fresh issue of shares worth ₹1,377.50 crore. The shares of Rubicon Research Limited will be listed on the BSE and NSE on its tentative listing date of October 16, 2025. Researching the Rubicon Research IPO, including its GMP and reviews, is highly recommended to secure your ideal level of profitability. Brokers and investors have highlighted their pros and cons, so one must analyse them and decide accordingly.

Open a demat account on Univest now to initiate your investment journey!

FAQs on Rubicon Research IPO

How is the Rubicon Research IPO?

Ans. As of 3rd October 2025, the Rubicon Research IPO GMP (Grey Market Premium) stands at ₹0. It indicates that the estimated listing price could be ₹485 per share. It is a book-building IPO of ₹1,377.50 crore. The face value of each share of Rubicon Research Limited is ₹1 per share.

What is the IPO price of Rubicon Research?

Ans. The Rubicon Research IPO price is set between ₹461 and ₹485 per share.  Retail investors can apply for a minimum of 1 lot, each consisting of 30 shares, worth ₹14,550. Moreover, HNIs are required to bid for a minimum of 14 lots (420 shares) worth ₹2,03,700.

Is the Rubicon Research IPO a good investment?

Ans. Rubicon Research Limited’s revenue increased by 49% from ₹872.39 crore in March 2024 to ₹1,296.22 crore in March 2025. Moreover, the company’s PAT rose by 48% from ₹91.01 crores to ₹134.36 crores.

Who is the registrar of the Rubicon Research IPO?

Ans. MUFG Intime India Private Limited is the registrar of the Rubicon Research IPO, responsible for managing the allotment procedure and initiating refunds. For any queries regarding the Rubicon Research allotment and refund, please contact MUFG Intime India Private Limited at ubicon.ipo@linkintime.co.in or +91-22-4918 6270.

What is the issue size of the Rubicon Research IPO?  

Ans. Rubicon Research‘s IPO is a book-building issue of ₹1,377.50 crore. Moreover, the IPO is set to open on 9th October 2025 and will be closed on 13th October 2025. 

Disclaimer: The above information is compiled from authentic sources and is just for informational purposes. To have detailed information about the Rubicon Research IPO, download the Rubicon Research IPO RHP and the Rubicon Research IPO DRHP. Conduct thorough research before investing in IPOs to minimise the risk of significant losses. You can also consult your financial advisor.

Upcoming IPOs

Current & Previous IPOs

Read Our Articles on the Best Stocks

Tech Stocks in India to Invest in 2025 | Tech Sector Stocks 

Best Battery Stocks in India to Invest in 2025 | Battery Sector Stocks 

Best Shipping Stocks in India to Invest in 2025 | Shipping Sector Stocks 

Paint Stocks in India to Invest in 2025 | Paint Sector Stocks 

Paper Stocks in India to Invest in 2025 | Paper Sector Stocks 

Best Semiconductor Stocks in India 2025 

Best Large Cap Stocks in India 2025 

Green Energy Penny Stocks

Best Cement Stocks To Invest in India

Also Explore

Univest Screeners

Explore Webstories on Univest 

1. Best Time To Buy Dividend Stocks

2. How RBI Policies Affect Dividend Stocks

3. Can Dividend Stocks Beat Inflation

4. What Is The Dividend Aristocrat List

5. Which Indian Psus Offer The Best Dividends

6. Large Cap Vs Small Cap Dividend Stocks